NLS Pharmaceutics (NASDAQ:NLSP; NASDAQ:NLSPW) has announced the launch of a preclinical program to evaluate Mazindol ER as a novel treatment for fentanyl dependence.
According to the Centers for Disease Control and Prevention (CDC), 90% of the 105,007 drug overdose deaths involved synthetic opioids such as fentanyl. The company stated that Mazindol ER is a potential non-opioid alternative that addresses the underlying neurochemical imbalances associated with fentanyl addiction.
Alex Zwyer, CEO of NLS, remarked, “The opioid epidemic, and specifically the rise of fentanyl dependence, presents an urgent medical need for innovative, non-opioid treatment approaches. “We are committed to exploring the unique pharmacological profile of Mazindol, which targets multiple neurotransmitter systems implicated in opioid addiction. This preclinical program represents an important step in developing a potentially transformative therapy.”
